Table 3.
Relationship Between LIPI Groups and Response to Anti-PD-1 Treatment
| Best Overall Response | No. of Patients (%) | P value | ||
|---|---|---|---|---|
| Overall n = 108 | Good LIPI n = 53 | Intermediate/Poor LIPI n = 55 | ||
| CR | 0 (0) | 0 (0) | 0 (0) | |
| PR | 23 (21.3) | 14 (26.4) | 9(16.4) | |
| SD | 54 (50.0) | 29 (54.7) | 25 (45.5) | |
| PD | 29 (26.9) | 9 (17.0) | 20 (36.4) | |
| Not assessablea | 2 (1.9) | 1 (1.9) | 1 (1.8) | |
| Objective response | 23 (21.3) | 14 (26.4) | 9 (16.4) | 0.242 |
| Disease control rate | 77 (71.3) | 43 (81.1) | 34 (61.8) | 0.029* |
Notes: * P < 0.05, statistically significant. aPatients who had baseline assessment by radiology but no postbaseline assessment by data cutoff date, including discontinuation or death before first postbaseline scan.